Skip to main content

Research Repository

Advanced Search

Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital. (2021)
Journal Article
AL ADAWI, R.M., ALBU-MAHMOOD, Z., ABDELGELIL, M., ABDELAZIZ, H., STEWART, D. and AWAISU, A. 2021. Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital. Risk management and healthcare policy [online], 14, pages 519-525. Available from: https://doi.org/10.2147/RMHP.S283471

Background: Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia. Objective: To determine the incidence of hyperkalemia and its risk factors in patients receiving co-trimoxazole. Materials and Methods: A retrospective observatio... Read More about Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital..

Ethanolic stem bark extract of terminalia ivorensis A. Chev. protects against potassium dichromate–induced nephrotoxicity in rats. (2020)
Journal Article
MOOMIN, A., MENSAH, K.B., FORKUO, A.D., ADU-GYAMFI, P.K.T. and ANSAH, C. 2020. Ethanolic stem bark extract of terminalia ivorensis A. Chev. protects against potassium dichromate-induced nephrotoxicity in rats. Scientific African [online], 8, article number e00410. Available from: https://doi.org/10.1016/j.sciaf.2020.e00410

Objective: The plant Terminalia ivorensis is used in traditional medicine as a diuretic and in the management of renal failure. We reported previously that the ethanol stem bark extract of the plant protects against gentamicin-induced renal and hepat... Read More about Ethanolic stem bark extract of terminalia ivorensis A. Chev. protects against potassium dichromate–induced nephrotoxicity in rats..

Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population. (2019)
Journal Article
AL ADAWI, R.M., JASSIM, Z., ELGAILY, D., ABDELAZIZ, H., SREE, B. and MOHAMED IBRAHIM, M.I. 2019. Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population. Scientific reports [online], 9, article 6864. Available from: https://doi.org/10.1038/s41598-019-43052-6

The effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is an essential issue for establishing a basis for prescribing dapagliflozin. This study aimed to assess the effectiveness of dapagliflozin in combination with o... Read More about Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population..

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. (2018)
Journal Article
ELEDRISI, M., SULEIMAN, N.N., SALAMEH, O., HAMAD, M.K., RABADI, O., MOHAMED, A., AL ADAWI, R. and SALAM, A. 2019. Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. Journal of clinical and translational endocrinology [online], 15, pages 35-36. Available from: https://doi.org/10.1016/j.jcte.2018.12.002

Insulin glargine is recombinant human insulin analog that is commonly used in patients with type 2 diabetes as well as those with type 1 diabetes. Pharmacokinetic and pharmacodynamics studies of insulin glargine had shown that it has an onset of acti... Read More about Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus..

Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. (2018)
Journal Article
JASSIM, Z., ELAJEZ, R., KHUDAIR, I., AL ANANY, R., AL-ADAWI, R.M. 2019. Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. Journal of pharmaceutical health services research [online], 10(1), pages 73-80. Available from: https://doi.org/10.1111/jphs.12240

Objective: Compare efficacy and safety of liraglutide (1.8 mg subcutaneous once daily) and exenatide (10 mcg subcutaneous twice daily) in uncontrolled type 2 diabetes at 26 and 52 weeks. Method: A retrospective observation study of uncontrolled type... Read More about Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study..